A randomized, double-blind, placebo-controlled 12-week dose-response study of rivoglitazone (CS-011) in patients with type 2 diabetes
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2009
At a glance
- Drugs Rivoglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 31 Aug 2018 Biomarkers information updated
- 27 Mar 2009 Planned number of patients changed from 180 to 250 as reported by ClinicalTrials.gov.
- 11 Dec 2008 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.